Skip to main content

Articles

Page 33 of 36

  1. This paper summarizes the body of literature about early-onset dementia (EOD) that led to recommendations from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. A broader dif...

    Authors: Mario Masellis, Kayla Sherborn, Pedro Rosa Neto, Dessa A Sadovnick, Ging-Yuek R Hsiung, Sandra E Black, Sadhana Prasad, Meghan Williams and Serge Gauthier
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S7
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  3. Alzheimer's disease (AD) is a common neurodegenerative disease characterized by the accumulation of extracellular plaques and intracellular tangles. Recent studies support the hypothesis that the accumulation ...

    Authors: Kristin R Wildsmith, Monica Holley, Julie C Savage, Rebecca Skerrett and Gary E Landreth
    Citation: Alzheimer's Research & Therapy 2013 5:33
    Content type: Review Published on:

  5. The growing population of persons with dementia in Canada and the provision of quality care for this population is an issue that no healthcare authority will escape. Physicians often view dementia as a difficu...

    Authors: Cheryl Cook and Kenneth Rockwood
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S6
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  6. While there have been no new medications approved for the treatment of Alzheimer's disease (AD) or other dementias in Canada since 2004, the Canadian Consensus Conference on the Diagnosis and Treatment of Deme...

    Authors: Nathan Herrmann, Krista L Lanctôt and David B Hogan
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S5
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  7. The Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) was held 3 to 4 May 2012 in Montreal, Quebec, Canada. A group of neuroimaging experts were assigned the task of rev...

    Authors: Amer M Burhan, Robert Bartha, Christian Bocti, Michael Borrie, Robert Laforce Jr, Pedro Rosa-Neto and Jean-Paul Soucy
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S4
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  8. In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and...

    Authors: Jean-Paul Soucy, Robert Bartha, Christian Bocti, Michael Borrie, Amer M Burhan, Robert Laforce Jr and Pedro Rosa-Neto
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S3
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  9. There have been several newly proposed sets of diagnostic criteria for Alzheimer's disease/mild cognitive impairment, advanced by the National Institute of Aging/Alzheimer's Association working groups in 2011 ...

    Authors: Howard Chertkow, Howard H Feldman, Claudia Jacova and Fadi Massoud
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S2
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  12. Advances in the field of blood biomarker discovery will help in identifying Alzheimer's disease in its preclinical stage, allowing treatment to be initiated before irreversible damage occurs. This review discu...

    Authors: Veer Bala Gupta, Ramani Sundaram and Ralph N Martins
    Citation: Alzheimer's Research & Therapy 2013 5:31
    Content type: Review Published on:

  13. In a symposium held at the Clinical Trials in Alzheimer's Disease conference in Monte Carlo, Monaco (29 to 31 October 2012) three different, not mutually exclusive approaches to improve and facilitate clinical...

    Authors: René Spiegel, Rachelle S Doody, Suzanne Hendrix and Kristin Kahle-Wrobleski
    Citation: Alzheimer's Research & Therapy 2013 5:29
    Content type: Viewpoint Published on:

  14. Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may diffe...

    Authors: Laura E Donovan, Eric B Dammer, Duc M Duong, John J Hanfelt, Allan I Levey, Nicholas T Seyfried and James J Lah
    Citation: Alzheimer's Research & Therapy 2013 5:32
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:102

  17. Despite the extensive mechanistic and pathological characterization of the amyloid precursor protein (APP)/presenilin-1 (PS-1) knock-in mouse model of Alzheimer's disease (AD), very little is known about the A...

    Authors: Scott J Webster, Adam D Bachstetter and Linda J Van Eldik
    Citation: Alzheimer's Research & Therapy 2013 5:28
    Content type: Research Published on:

  19. Addressing causes of heterogeneity in cognitive outcomes is becoming more critical as Alzheimer's disease (AD) research focuses on earlier disease. One of the causes of this heterogeneity may be that individua...

    Authors: Suzanne B Hendrix and Kathleen A Welsh-Bohmer
    Citation: Alzheimer's Research & Therapy 2013 5:22
    Content type: Commentary Published on:

  20. Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has ge...

    Authors: Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta and David Schubert
    Citation: Alzheimer's Research & Therapy 2013 5:25
    Content type: Research Published on:

  22. Alzheimer's disease (AD), for which there is no cure, is the most common form of dementia in the elderly. Despite tremendous efforts by the scientific community, the AD drug development pipeline remains extrem...

    Authors: Laurent Lecanu and Vassilios Papadopoulos
    Citation: Alzheimer's Research & Therapy 2013 5:17
    Content type: Review Published on:

  23. The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target s...

    Authors: Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker and Allan I Levey
    Citation: Alzheimer's Research & Therapy 2013 5:21
    Content type: Review Published on:

  24. During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only...

    Authors: María Javier Ramírez
    Citation: Alzheimer's Research & Therapy 2013 5:15
    Content type: Review Published on:

  26. Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of ...

    Authors: Robyn M Loureiro, Jo Ann Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk and Barbara Tate
    Citation: Alzheimer's Research & Therapy 2013 5:19
    Content type: Research Published on:

  28. Curcuminoids may improve pathological conditions associated with Alzheimer's disease. However, their therapeutic potential is limited by their exceedingly low bioavailability after oral administration. A metho...

    Authors: Wolfgang W Quitschke, Nicole Steinhauff and Jean Rooney
    Citation: Alzheimer's Research & Therapy 2013 5:16
    Content type: Research Published on:

  33. Heterogeneity in risk of conversion to Alzheimer's disease (AD) among individualswith mild cognitive impairment (MCI) is well known. Novel statistical methods thatare based on partially ordered set (poset) mod...

    Authors: Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth and Alan J Lerner
    Citation: Alzheimer's Research & Therapy 2013 5:14
    Content type: Research Published on:

  34. The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with ...

    Authors: Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell and Randi Fain
    Citation: Alzheimer's Research & Therapy 2013 5:12
    Content type: Research Published on:

  35. The clinical, neuropsychiatric and neuroimaging features of patients who carry the important new C9ORF72 mutation are discussed in this special series of Alzheimer's Research & Therapy. First reported in November...

    Authors: Bruce L Miller
    Citation: Alzheimer's Research & Therapy 2013 5:7
    Content type: Editorial Published on:

  36. The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alz...

    Authors: Rachel F Lane, Penny A Dacks, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2013 5:5
    Content type: Meeting report Published on:

  37. The characteristics of dementia relating to excessive alcohol use have received increased research interest in recent times. In this paper, the neuropathology, nosology, epidemiology, clinical features, and ne...

    Authors: Nicole J Ridley, Brian Draper and Adrienne Withall
    Citation: Alzheimer's Research & Therapy 2013 5:3
    Content type: Review Published on:

  38. Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine...

    Authors: Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte and David Wilkinson
    Citation: Alzheimer's Research & Therapy 2013 5:6
    Content type: Research Published on:

  39. 18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....

    Authors: Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger and Christopher C Rowe
    Citation: Alzheimer's Research & Therapy 2013 5:4
    Content type: Research Published on:

  40. With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that emphasize prototypic illness continu...

    Authors: Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss and Sandra E Black
    Citation: Alzheimer's Research & Therapy 2013 5:1
    Content type: Review Published on:

  44. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2 activ...

    Authors: Julie E Davidson, Andrew Lockhart, Leslie Amos, Heide A Stirnadel-Farrant, Vincent Mooser, Marc Sollberger, Axel Regeniter, Andreas U Monsch and Michael C Irizarry
    Citation: Alzheimer's Research & Therapy 2012 4:51
    Content type: Research Published on:

  46. Frontotemporal dementia (FTD) is a common dementia syndrome in patients under the age of 65 years with many features overlapping with amyotrophic lateral sclerosis (ALS). The link between FTD and ALS has been ...

    Authors: Sharon J Sha and Adam Boxer
    Citation: Alzheimer's Research & Therapy 2012 4:46
    Content type: Review Published on:

  48. Hexanucleotide expansion intronic to chromosome 9 open reading frame 72 (C9ORF72) has recently been identified as the most common genetic cause of both familial and sporadic amyotrophic lateral sclerosis and of f...

    Authors: Jennifer S Yokoyama and Howard J Rosen
    Citation: Alzheimer's Research & Therapy 2012 4:45
    Content type: Review Published on:

  50. Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It...

    Authors: John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman…
    Citation: Alzheimer's Research & Therapy 2012 4:43
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193